Form 4: CG Oncology Director Susan Graf Granted 24,165 Stock Options

CG Oncology, Inc. Director Susan E. Graf was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over a year, as part of her compensation.

Summary

• Susan E. Graf, a Director of CG Oncology, Inc. (CGON), was granted 24,165 stock options.
• The options have an exercise price of $26.63 per share.
• The grant date for these options was June 5, 2025.
• The options will vest monthly, with 1/12th of the total shares vesting each month following the grant date.
• Any remaining unvested portion will vest on the date of the next annual meeting of stockholders if it occurs prior to the first anniversary of the grant date.
• Vesting is contingent upon Ms. Graf's continuous service to the Issuer.
• The options expire on June 4, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive as it indicates standard director compensation, aligning interests with shareholders. It does not contain any negative news or significant positive operational updates.

Positives

• The grant of stock options aligns the director's interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The value of the stock options is dependent on the future stock price of CG Oncology, Inc. exceeding the exercise price of $26.63.
• Vesting is subject to continuous service, meaning the options could be forfeited if the director's service terminates.

Future Outlook

This filing does not provide forward-looking statements regarding the company's financial performance or strategic direction, but rather details a compensation grant to a director.

Management Comments

• 1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation in the biotechnology or pharmaceutical industry, where equity grants are a common component of executive and director remuneration to align interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across various industries, including biotechnology, to incentivize long-term commitment and performance.
• The vesting schedule of monthly over a year, with accelerated vesting upon an earlier annual meeting, is a common structure for director equity awards, comparable to practices seen in companies like Amgen or Gilead Sciences for similar roles.
• The exercise price being set at the market price on the grant date is typical for non-qualified stock options granted to directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially leading to better long-term performance and value creation.

Next Steps

• The options will begin vesting monthly from June 5, 2025, subject to continuous service.
• The director will have the right to exercise these options at any time after vesting and before the expiration date of June 4, 2035.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Rule 10b5-1